Bio/Pharma Business

Predictive Oncology and Cvergenx Enter Genomics-Based Personalized Therapy Collaboration

February 24, 2023

The goal of this collaboration is to develop an approach to personalized radiotherapy and drug discovery that is based in genomics and artificial intelligence.

LIfT BioSciences and Minaris Regenerative Enter Cell Therapy Partnership

February 21, 2023

LIfT and Minaris will work together to develop a manufacturing process for LIfT’s allogeneic neutrophil progenitor cell therapy.

Takeda Completes $6 Billion Acquisition of Nimbus Therapeutics Subsidiary

February 15, 2023

Takeda’s acquisition of Nimbus Lakshmi will grant them rights to NDI-034858, an oral, selective allosteric TYK2 inhibitor being evaluated for the treatment of multiple autoimmune diseases.

Forecasting Trends in Pharma Innovation

February 15, 2023

In the coming year, pharmaceutical innovation will be fueled by key trends throughout the quality sector.

The COVID-19 Pandemic and Its Positive Impact on RNA Drug Development

February 15, 2023

The COVID-19 pandemic helped to showcase RNA molecules and their therapeutic potential. There were also lessons learned in terms of drug delivery, manufacturing, logistics, and storage.

Biden Hits Drug Prices for Boosting Health Care Costs

February 09, 2023

Biden outlined a host of priorities for improving health care and building the economy during State of the Union address.

Pharmapack Europe Announces Winners of Pharmapack 2023 Awards

February 08, 2023

Pharmapack Europe has announced the winners of the 2023 Pharmapack Awards spanning five categories across two dedicated awards.

Astellas to Appoint New CEO and President

February 07, 2023

Naoki Okamura, Astellas’ current chief strategy officer, will take over the role from Kenji Yasukawa.

Thermo Fisher Scientific Announces Founding Sponsorship of Momentum Labs

February 06, 2023

Thermo Fisher’s sponsorship of Momentum Labs is intended to support biotech businesses in the greater Gainesville region.

Proportion, Balance, and Restraint

February 02, 2023

The restraint to not target solely the major disease groups has provided good proportion and balance for our industry.